Company Encyclopedia
View More
name
Tellgen
300642.SZ
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.
341.32 B
300642.SZMarket value -Rank by Market Cap -/-

Financial Score

10/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking31/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.07%D
    • Profit Margin4.26%C
    • Gross Margin70.27%A
  • Growth ScoreD
    • Revenue YoY-19.26%E
    • Net Profit YoY-77.55%E
    • Total Assets YoY18.56%A
    • Net Assets YoY0.40%C
  • Cash ScoreC
    • Cash Flow Margin2346.38%A
    • OCF YoY-19.26%E
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreB
    • Gearing Ratio23.63%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tellgen released its performance for the first three quarters, with a net profit attributable to the parent company of 5.7749 million yuan, a decrease of 76.33%

    Tellgen released its Q3 2025 report, with operating revenue for the first three quarters amounting to 258 million yuan, a year-on-year decrease of 19.73%. The net profit attributable to the parent company was 5.7749 million yuan, a year-on-year decline of 76.33%; the net profit after deducting non-recurring gains and losses was 1.3732 million yuan, a year-on-year decrease of 90.45%. The basic earnings per share were 0.0356 yuan

    Zhitong·
    SZ
    300642
    -0.85%
    Zhitong·
    SZ
    300642
    -0.85%

    Tellgen: Completed the repurchase of 737,000 shares

    Tellgen announced that the company will repurchase 737,000 shares through centralized bidding from August 28, 2025, to September 30, 2025, accounting for 0.45% of the company's current total share capital. The maximum repurchase price is RMB 29.34 per share, the minimum price is RMB 23.89 per share, and the total amount is RMB 20.0269 million. All repurchased shares will be used for the employee stock ownership plan or equity incentive plan

    Zhitong·
    SZ
    300642
    -0.85%
    Zhitong·
    SZ
    300642
    -0.85%

    Tellgen: First repurchase of 0.13% of the company's shares

    Tellgen announced that on August 28, 2025, the company first implemented a share repurchase of 211,200 shares through a dedicated stock repurchase account via centralized bidding, accounting for 0.13% of the company's current total share capital. The highest transaction price for the repurchased shares was RMB 29.34 per share, the lowest transaction price was RMB 27.3 per share, and the total amount paid was RMB 5.9071 million. This repurchase complies with the company's established repurchase plan and relevant laws and regulations

    Zhitong·
    SZ
    300642
    -0.85%
    Zhitong·
    SZ
    300642
    -0.85%

    Tellgen: Net profit of 2.7593 million yuan in the first half of 2025, a year-on-year decrease of 58.41%

    Tellgen announced that its operating revenue in the first half of 2025 was 159 million yuan, a year-on-year decrease of 26.25%. The net profit was 2.7593 million yuan, a year-on-year decrease of 58.41%

    Zhitong·
    SZ
    300642
    -0.85%
    Zhitong·
    SZ
    300642
    -0.85%

    The gene sequencing sector surged in the short term, and Berry Genomics hit the limit up

    The gene sequencing sector saw a short-term surge, with Berry Genomics hitting the limit up, while MGI, Dian Diagnostics, Antu Biology, Wavelength OE, Tellgen, and others all rose

    Zhitong·
    SZ
    301421
    +2.82%
    SZ
    300642
    -0.85%
    SH
    688114
    +0.83%
    Zhitong·
    SZ
    301421
    +2.82%
    SZ
    300642
    -0.85%
    SH
    688114
    +0.83%
    © 2025 Longbridge｜Disclaimer